Circulating Tumor Cells and Circulating Tumor DNA in Colorectal Cancer

References

• Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J. 1869;14:146–149.
   Google Scholar
• Onuigbo WIB. A history of hematogenous metastasis. Cancer Res. 1970;30(12):2821–2826.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–361.
   PubMed Web of Science ®Google Scholar
• Hüsemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13(1):58–68.
   PubMed Web of Science ®Google Scholar
• Méhes G, Witt A, Kubista E, et al.. Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001;159(1):17–20.
   PubMed Web of Science ®Google Scholar
• Mandel P, Métais P. Les acides nucléiques du plasma sanguin chez l‘homme. C R Acad Sci Paris. 1948;142:241–243.
   Google Scholar
• Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3(1):67–71.
   PubMed Web of Science ®Google Scholar
• Rogers A, Joe Y, Manshouri T, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood. 2003;103(7):2799–2801.
   PubMed Web of Science ®Google Scholar
• Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med. 1996;2(9):1035–1037.
   PubMed Web of Science ®Google Scholar
• Jernimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2015;60(6):1131–1135.
   Google Scholar
• Choi -J-J, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology. 2005;115(1):55–62.
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, et al. Group O behalf of the EGW. Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v70–v77.
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Cunningham D, Mikropoulos C, et al. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol. 2010;21(5):1013–1019.
   PubMed Web of Science ®Google Scholar
• Cima I, Wen Yee C, Iliescu FS, et al. Label-free isolation of circulating tumor cells in microfluidic devices: current research and perspectives. Biomicrofluidics. 2013;7(1):11810.
   PubMed Web of Science ®Google Scholar
• Mavligit GM, Gutterman JU, Harsh EM. Separation of viable from non-viable tumor cells using Ficoll-Hypaque density solution. Immunol Invest. 1973;2(5):463–472.
   Google Scholar
• Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol. 2000;156(1):57–63.
   PubMed Web of Science ®Google Scholar
• Desitter I, Guerrouahen BS, Benali-Furet N, et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011;31(2):427–441.
   PubMed Web of Science ®Google Scholar
• Lim LS, Hu M, Huang MC, et al. Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip. 2012;12(21):4388.
   PubMed Web of Science ®Google Scholar
• Tan SJ, Lakshmi RL, Chen P, et al. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron. 2010;26(4):1701–1705.
   PubMed Web of Science ®Google Scholar
• Gupta V, Jafferji I, Garza M, et al. ApoStreamTM, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics. 2012;6(2):1–14.
   Web of Science ®Google Scholar
• Alix-Panabières C, Brouillet J-P, Fabbro M, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods. 2005;299(1–2):177–188.
   PubMed Web of Science ®Google Scholar
• Dotan E, Cohen SJ, Alpaugh KR, et al. Circulating tumor cells: evolving evidence and future challenges. Oncologist. 2009;14(11):1070–1082.
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94(1):128–135.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64(5):415–420.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RYJ, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2015;139(5):871–890.
   Web of Science ®Google Scholar
• Mikolajczyk SD, Millar LS, Tsinberg P, et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol. 2011;2011:1–10.
   Google Scholar
• Bidard F-C, Hajage D, Bachelot T, et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res. 2012;14(1):R29.
   PubMed Web of Science ®Google Scholar
• Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105(6):847–853.
   PubMed Web of Science ®Google Scholar
• Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–6904.
   PubMed Web of Science ®Google Scholar
• Wu Y, Deighan CJ, Miller BL, et al. Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods. 2013;64(2):169–182.
   PubMed Web of Science ®Google Scholar
• Karabacak NM, Spuhler PS, Fachin F, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014;9(3):694–710.
   PubMed Web of Science ®Google Scholar
• Gerges N, Rak J, Jabado N. New technologies for the detection of circulating tumour cells. Br Med Bull. 2010;94(1):49–64.
   PubMed Web of Science ®Google Scholar
• Friedlander TW, Ngo VT, Dong H, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2014;134(10):2284–2293.
   PubMed Web of Science ®Google Scholar
• Takakura M, Kyo S, Nakamura M, et al. Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers. Br J Cancer. 2012;107(3):448–454.
   PubMed Web of Science ®Google Scholar
• Galanzha EI, Shashkov EV, Kelly T, et al. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol. 2009;4(12):855–860.
   PubMed Web of Science ®Google Scholar
• Saucedo-Zeni N, Mewes S, Niestroj R, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241–1250.
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20(7):1223–1229.
   PubMed Web of Science ®Google Scholar
• Bork U, Rahbari NN, Schölch S, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112(8):1306–1313.
   PubMed Web of Science ®Google Scholar
• Maestro LM, Sastre J, Rafael SB, et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res. 2009;29(11):4839–4843.
   PubMed Web of Science ®Google Scholar
• Huang X, Gao P, Song Y, et al. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer. 2014;14(1):1–15.
   PubMed Web of Science ®Google Scholar
• Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–1239.
   PubMed Web of Science ®Google Scholar
• Kim STAE, Sohn I, Do I-G, et al. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genom Proteom. 2014;11(5):259–266.
   PubMed Web of Science ®Google Scholar
• Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci. 2009;106(10):3970–3975.
   PubMed Web of Science ®Google Scholar
• Sastre J, Maestro ML, Gómez-España A, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish cooperative group for the treatment of digestive tumors study. Oncologist. 2012;17(7):947–955.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Lenz H-J, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–948.
   PubMed Web of Science ®Google Scholar
• Mostert B, Jiang Y, Sieuwerts AM, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130–141.
   PubMed Web of Science ®Google Scholar
• Mohamed Suhaimi N-A, Foong YM, Lee DYS, et al. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol. 2015;9(4):850–860.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti–epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–2096.
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995.
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327.
   PubMed Web of Science ®Google Scholar
• Stoffel EM, Mangu PB, Gruber SB, et al.. Hereditary colorectal cancer syndromes: American society of clinical oncology clinical practice guideline endorsement of the familial risk – colorectal cancer: European society for medical oncology clinical practice guidelines. J Clin Oncol. 2015;33(2):209–217.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol. 2013;31(35):4465–4470.
   PubMed Web of Science ®Google Scholar
• Labianca R, Nordlinger B, Beretta GD, et al.. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6) (April 2002):vi64–72.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1–iii9.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines for colon cancer version 1.2014 [Internet]. 2014. Available from: http://www.nccn.org/patients/guidelines/colon/index.html#.
   Google Scholar
• Workgroup TSCN (SCAN) CCST. Singapore cancer network (SCAN) guidelines for systemic therapy of colorectal cancer. Ann Acad Med Singapore. 2015;44:379–387.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl. 2014;6:224.
   Web of Science ®Google Scholar
• Tomochika S, Iizuka N, Watanabe Y, et al. Increased serum cell-free DNA levels in relation to inflammation are predictive of distant metastasis of esophageal squamous cell carcinoma. Exp Ther Med. 2010;1(1):89–92.
   PubMed Web of Science ®Google Scholar
• Spindler K-LG, Pallisgaard N, Vogelius I, et al. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18(4):1177–1185.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430–435.
   PubMed Web of Science ®Google Scholar
• Taly V, Pekin D, Benhaim L, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59(12):1722–1731.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102(45):16368–16373.
   PubMed Web of Science ®Google Scholar
• Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra154–162ra154.
   PubMed Web of Science ®Google Scholar
• Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015;9(4):783–790.
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al.. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. advance on 2014;20(5):548–554.
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson S-J, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–112.
   PubMed Web of Science ®Google Scholar
• Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–1209.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Ulz P, Belic J, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013;5(9):30.
   PubMed Web of Science ®Google Scholar
• Heitzer E, Auer M, Gasch C, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73(10):2965–2975.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–536.
   PubMed Web of Science ®Google Scholar
• Frenel JS, Carreira S, Goodall J, et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res. 2015;21(20):4586–4596.
   PubMed Web of Science ®Google Scholar
• Lefebure B, Charbonnier F, Fiore FD, et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. Ann Surg. 2010;251(2):275–280.
   PubMed Web of Science ®Google Scholar
• Spindler KLG, Pallisgaard N, Andersen RF, et al. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One. 2015;10(4):e0108247.
   PubMed Web of Science ®Google Scholar
• Lin J-K, Lin P-C, Lin C-H, et al. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. Ann Surg Oncol. 2014;21(S4):680–686.
   Web of Science ®Google Scholar
• Reinert T, Scholer LV, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2015;1–10. doi:10.1136/gutjnl-2014-308859
   Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
   PubMed Web of Science ®Google Scholar